Abbasi and another (Respondents) v Newcastle upon Tyne Hospitals NHS Foundation Trust (Appellant);Haastrup (Respondent) v King’s College Hospital NHS Foundation Trust (Appellant) [2015] UKSC 15 (Link to UKSC).
The text below is copied from the UKSC press summary.
Justices: Lord
Pointing to renewed optimism in healthcare transactions, Diwakar Sinha suggests that “2025 looks very promising and should be a very successful year in the M&A space.” As founder and CEO of Polaris Healthcare Partners, Diwakar shares insights on the
On April 14, U.S. District Judge Matthew F. Kennelly ruled, in relevant part, that the U.S. Department of Labor (DOL) cannot require federal grant recipients to certify that their diversity, equity and inclusion (DEI) programs do not violate applicable
Whistleblower Law Collaborative LLC is pleased to announce that the United States has settled a False Claims Act case alleging genetic testing fraud brought by two of its clients against Genexe, LLC d/b/a Genexe Health, Immerge, Inc., the parent company
As we stride further into 2025, the pharmacy industry faces a landscape teeming with challenges and opportunities. From tackling drug price transparency to juggling implementation of artificial intelligence, the industry is being transformed before our eyes. The journey ahead is
FDA has issued two Federal Register notices in under two weeks that seek comments on updates to FDA data standards.
The number of U.S. states implementing or considering new antitrust laws (or supplementing existing laws) targeting proposed transactions continues to grow. As detailed in our healthcare merger matrix, many states have focused their attention on the healthcare industry, and
Cass.com 12 février 2025 n°23-16.290
Intégrée dans certains pactes d’associés, la clause d’offre alternative ou de « buy or sell » a pour ambition de permettre de résoudre des situations persistantes de conflit ou de blocage entre associés en organisant la sortie
On April 18, U.S. Food and Drug Administration (FDA) Commissioner Marty Makary announced plans to roll-out a new approval pathway for rare disease drugs. Commissioner Makary’s comments build on sentiments expressed across both the patient community and industry that rare